



Nanomedicines ALLIANCE

NanoMed Digest

Amgen • AstraZeneca • Cerulean Pharma Inc. • CytImmune • Liquidia Technologies •
Nanobiotix • NanoCarrier Co. Ltd. • NanoViricides, Inc. • Pfizer

Join the Nanomedicines Alliance. Contact us at info@nanomedicines-alliance.org.

Legislative and Regulatory Highlights

National Nanotechnology Initiative Strategic Plan

The US National Nanotechnology Initiative (NNI) has published its 2016 Strategic Plan, following a public comment of several weeks. Several comments on the draft document requested that NNI increase stakeholder engagement, by publicizing assessment reports and documentation for new nanotechnologies, as well as disseminating regulatory information. The Strategic Plan focuses on “creating an ecosystem that supports all aspects of the nanotechnology enterprise from fundamental discovery to commercial products.” NNI also stresses the need for collaboration across the nanotechnology community. Among other organizations that participated in the NNI stakeholder workshop, the Nanomedicines Alliance is recognized as a significant contributor to NNI’s 2016 strategy. The announcement and the link to the strategic plan [may be found here](#).

NNI Celebrates National Nanotechnology Day

The NNI has released dozens of “[Nano Nuggets](#)” in honor of National Nanotechnology Day, October 9. These “nuggets” are short videos featuring experts discussing interesting developments in nanotechnology. The videos include Dr. Nicole Steinmetz discussing how [nanotechnology is enabling the development of personalized medicine](#), Dr. Sangeeta Bhatia discussing the [impact of nanotechnology on detecting and treating disease](#), Dr. Angelique Johnson on the [impact of nanotechnology on medical devices](#) over the next five years.

European Chemicals Agency to Gather Information on Nanomaterials

The European Commission (EC) has tasked the European Chemicals Agency (ECHA) with the creation and management of a [European Union Observatory for Nanomaterials](#). ECHA will gather data from REACH registrations, scientific opinions and EC documentation, national registries, market studies, industry, worker, and consumer organizations, among other sources. According to the published agreement, the main aim of the Observatory is to give objective and reliable information on markets and safety aspects of nanomaterials in the EU market, including food and medicines. The European Commission also intends to review the definition of nanomaterials in the near future.

Business News

[Nanobiotix](#) is reporting positive results in preliminary data from a Phase I/II trial evaluating NBTXR3 in liver cancers. The preliminary data also demonstrate safety and feasibility of the treatment.

[Keystone Nano](#) announced on October 18, 2016 that it has received orphan drug designation from FDA for the use of ceramide to treat liver cancer.

For further information, or if you have any questions about the Nanomedicines Alliance, please contact the Nanomedicines Alliance Secretariat at info@nanomedicines-alliance.org.

[Precision NanoSystems Inc.](#) has created a device that produces “self-assembling” molecules that target drugs and gene therapies to specific cells.

[Nanobiomed Inc.](#) has developed a new molecule, Prextrolin®, for use in tissue and cancer diagnostics. Prextrolin® is reported to behave like a biological marker.

Conferences and Workshops

[New Tools and Approaches for Nanomaterial Safety Assessment](#), 7 – 9 February 2017, Malaga, India

Risk assessment
Safety by design

[Advances in Biological Systems and Materials Science in NanoWorld](#), 19 – 23 February 2017, Varanasi, India

Nano-biotechnology and nanomedicine
Nanostructures for biological applications
Nanotoxicology

[International Conference on Nanomedicine, Drug Delivery, and Tissue Engineering](#), 4 – 6 April 2017, Barcelona, Spain

Cancer and Nanotechnology
Clinical Applications
Gene Delivery Systems
Nanomedicine
Biomedical Applications
Drug Delivery
Detection
Imaging

[EuroNanoForum](#), 21 – 23 June 2017, Valletta, Malta

Nanomedicine
Nano-enabled healthcare
Enabling public-private partnership

Reference Section

Nano Organizations

[National Center for Toxicological Research \(NCTR\)](#)

[National Nanotechnology Initiative \(NNI\)](#)

[Nano Science and Technology Consortium \(NSTC\)](#)

[Nano Science and Technology Institute \(NSTI\)](#)

[The Nanotechnology Institute \(NTI\)](#)

Nano Journals

[American Chemical Society -- Nano Letters](#)

[Institute of Physics – Nanotechnology](#)

[Journal of Nanoscience and Nanotechnology](#)

[NanoTrends - A Journal of Nanotechnology and its Applications](#)

[BCC Research -- Nanotechnology Reports](#)

[Nanomedicine: Nanotechnology, Biology, and Medicine](#)

[Future Medicine](#)

[Nature Nanotechnology](#)

Contact

For further information, or if you have any questions about the Nanomedicines Alliance, please contact the Nanomedicines Alliance Secretariat at 1-202-230-5653 or info@nanomedicines-alliance.org.

This newsletter is provided as a public service and resource to the scientific and regulatory community interested in nanomedicines. The mention of any organizations, conferences or other events in this newsletter IS FOR INFORMATIONAL PURPOSES ONLY and does not represent an endorsement by the Nanomedicines Alliance or any of its members.

For further information, or if you have any questions about the Nanomedicines Alliance, please contact the Nanomedicines Alliance Secretariat at info@nanomedicines-alliance.org.